Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMAHOEP)

Drug Name
GRNVAC1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMAHOEP

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Telomerase reverse transcriptase (TERT) TTUJFD0 TERT_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Telomerase reverse transcriptase (TERT) DTT TERT 1.848 3.217 2.485 3.406
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Telomerase reverse transcriptase (TERT) DTT TERT 8.59E-10 -0.08 -0.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00510133) A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health.
2 Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42.